CECambridge Epigenetix Team
Cambridge Epigenetix
Last updated: February 23, 2026
Cambridge Epigenetix is using epigenetics to reduce diagnostic tests for common cancers to a simple blood draw. Biotech Healthcare Medical
Sequoia, $88M Series D in 2021, $350M valuation
Cambridge Epigenetix is using epigenetics to reduce diagnostic tests for common cancers to a simple blood draw. Biotech Healthcare Medical
Sequoia, $88M Series D in 2021, $350M valuation
- Series D • Sequoia, $88M Series D in 2021, $350M valuation
Founder Intelligence Brief: Cambridge Epigenetix Team
This profile is built to help readers move from a founder name to decision-ready context. Cambridge Epigenetix Team is mapped to Cambridge Epigenetix in the Startup category, with current stage context as Series D. The primary operating market is London, England, United Kingdom, which connects this profile directly to regional ecosystem pages and related industry hubs.
Funding visibility currently shows $88.00M, with the latest mapped round as Series D (Sequoia, $88M Series D in 2021, $350M valuation). This makes it easier to evaluate growth narrative against capital stage rather than reading isolated updates without baseline context.
For deeper research, combine this founder page with the company profile, company news hub, country newsroom and Startup startup list. This route gives a cleaner picture of execution, market demand, and competitive movement.
Research flow
- Validate company baseline on company intelligence.
- Compare market peers via Startup industry routes and Series D stage pages.
- Track fresh updates in newsroom coverage and signals feed.
Operating context
- Geography: United Kingdom directory.
- Stage signal: Series D funding coverage.
- Hiring status: Open Roles.
Related Founders
More founders in Startup.
Want to get featured on 100Xfounder?
Get your founder profile published with verified funding and hiring context.
Related Pillar Pages
Access the country, industry, stage, startup taxonomy, and newsroom routes connected to this founder.
FAQs About Cambridge Epigenetix Team
Common questions people ask about this profile.
Who is Cambridge Epigenetix Team?
Cambridge Epigenetix Team is the founder profile listed on 100Xfounder for Cambridge Epigenetix, tracked for market signals, company intelligence, and operator-level context.
What does Cambridge Epigenetix do?
Cambridge Epigenetix is using epigenetics to reduce diagnostic tests for common cancers to a simple blood draw. Biotech Healthcare Medical
Where is Cambridge Epigenetix based?
Cambridge Epigenetix is listed as operating from London, England, United Kingdom.
What is the current funding stage of Cambridge Epigenetix?
Cambridge Epigenetix is currently categorized at Series D on 100Xfounder. Funding signal: Sequoia, $88M Series D in 2021, $350M valuation
What is the latest funding round for Cambridge Epigenetix?
The latest tracked round for Cambridge Epigenetix is Series D Sequoia, $88M Series D in 2021, $350M valuation. Total tracked rounds: 1.
Is Cambridge Epigenetix hiring right now?
Current hiring signal for Cambridge Epigenetix: Open Roles.
Is Cambridge Epigenetix Team's profile verified?
Yes. Cambridge Epigenetix Team's profile is marked as verified on 100Xfounder as of March 3, 2026.
How can I connect with Cambridge Epigenetix Team?
You can use the profile action buttons and listed links on 100Xfounder. Contact context is provided with business relevance and profile metadata for www.cambridge-epigenetix.com.
What technologies are associated with Cambridge Epigenetix?
Cambridge Epigenetix is associated with AWS, React, Python, and PostgreSQL based on current profile intelligence.